Jiangsu Jibeier Pharmaceutical (SHSE:688566) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something concerni
North China Pharmaceutical Company.Ltd (SHSE:600812) Strong Profits May Be Masking Some Underlying Issues
North China Pharmaceutical Company.Ltd (SHSE:600812) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weak
Express News | Sinqi Eye Medicine: Aier Eye Hospital Group and others have reached a cooperation with the company and will introduce low-concentration atropine in the near future
Express News | Sinqi Pharmaceutical: After 0.01% atropine sulfate eye drops were approved, the production line was uninterrupted for 24 hours
Huaxia Ophthalmology (301267): The 24Q1 performance growth rate has slowed, and the implementation of mergers and acquisitions is expected to increase annual results
Core view: Huaxia Ophthalmology announced the 2023 and 2024Q1 results. The company achieved operating income of 4,013 billion yuan in 2023, +24.12% year-on-year; net profit to mother was 666 million yuan, +29 million yuan year-on-year.
Jianghe Group (601886): The leading curtain wall player, Hengqiang Industry maintained rapid growth under pressure, and the dividend ratio increased dramatically
Incident: The company achieved revenue of 4,086 billion yuan in 2024Q1, an increase of 19.50%, and net profit to mother of 182 million yuan, an increase of 11.10%. After deducting net profit of non-return to mother, it was 177 million yuan, an increase of 21.87%. spot